EXPORT CITATION

Chapter-05 Thrombin-activable Fibrinolysis Inhibitor (TAFI): An Important Contributor in the Fibrinolytic System

BOOK TITLE: Recent Advances in Hematology-3

Author
1. Saxena Renu
2. Biswas Arijit
3. Akhter Suhail
ISBN
9788184488883
DOI
10.5005/jp/books/11240_5
Edition
1/e
Publishing Year
2011
Pages
7
Author Affiliations
1. All India Institute of Medical Sciences, New Delhi (India), All India Institute of Medical Sciences (AIIMS), Ansari Nagar, New Delhi, All India Institute of Medical Sciences, New Delhi, India, All India Institute of Medical Sciences, New Delhi, Medanta–The Medicity, Gurugram, Haryana, India, Medanta - The Medicity, Gurugram, Haryana, India; All India Institute of Medical Sciences, New Delhi, India
2. YLL School of Medicine, National University of Singapore, Yong Loo Lin School of Medicine, National University of Singapore, Institute of Hematology and Transfusion Medicine, Germany, National University Hospital, Singapore
3. All India Institute of Medical Sciences, New Delhi, India
Chapter keywords

Abstract

Thrombin-activable fibrinolysis Inhibitor (TAFI) is a basic carboxypeptidase, which inhibits fibrinolysis by cleaving the C-terminal lysine residues on plasmin modified partially degraded fibrin. An increasing number of studies are finding a role for this inhibitor in a arge number of prothombotic disorders like stoke and coronary artery disease. What makes this candidate even more interesting is that the antigenic levels of TAFI shows a stringent association with SNPs found mostly on regulatory regions of the TAFI gene. The human TAFI gene is located on chromosome 13q14.11 and consists of 11 exons spanning approximately 48kb. TAFI is involved in the regulation of fibrinolysis and is therefore considered an attractive potential new drug target for the treatment of thrombotic disorders.

Related Books

© 2019 Jaypee Brothers Medical Publishers (P) LTD.   |   All Rights Reserved